Ophthalmic pharmaceutical company Tenpoint Therapeutics Ltd announced on Friday a New Drug Submission to Health Canada seeking approval of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults.
The once-daily combination eye drop was approved by the US Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent treatment of its kind for the condition.
The submission is supported by positive results from two Phase 3 clinical trials, BRIO I and BRIO II, in which YUVEZZI significantly improved near vision with once-daily administration. The treatment also demonstrated pupil constriction lasting from 30 minutes to 10 hours and was well tolerated, with no treatment-related serious adverse events reported across more than 72,000 dosing days monitored in BRIO II.
Presbyopia, the gradual loss of close-up vision that typically begins around age 45, affects approximately 2 billion people worldwide. The Canadian regulatory submission represents another step in Tenpoint's efforts to expand YUVEZZI's availability to patients globally.
Harbour BioMed's partner Spruce Biosciences separates CRHX-101 into Adrenyx Biosciences
US FDA clears Medtronic plc's Hugo robotic-assisted surgery system for general surgery
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder